VIR BIOTECHNOLOGY INC's ticker is VIR and the CUSIP is 92764N102. A total of 145 filers reported holding VIR BIOTECHNOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $399,922 | -15.8% | 44,935 | -4.2% | 0.00% | -75.0% |
| Q1 2024 | $475,188 | -0.8% | 46,909 | -1.4% | 0.00% | 0.0% |
| Q4 2023 | $478,846 | +0.6% | 47,599 | -6.3% | 0.00% | 0.0% |
| Q3 2023 | $476,174 | -25.8% | 50,819 | +94.2% | 0.00% | -33.3% |
| Q2 2023 | $641,778 | -2.4% | 26,163 | -7.4% | 0.01% | 0.0% |
| Q1 2023 | $657,378 | -20.1% | 28,250 | -13.1% | 0.01% | -25.0% |
| Q4 2022 | $822,929 | +10.6% | 32,514 | -15.7% | 0.01% | -11.1% |
| Q3 2022 | $744,000 | -23.0% | 38,580 | +3.9% | 0.01% | -10.0% |
| Q2 2022 | $966,000 | -14.4% | 37,144 | -14.7% | 0.01% | 0.0% |
| Q1 2022 | $1,128,000 | -10.5% | 43,535 | +40.3% | 0.01% | 0.0% |
| Q4 2021 | $1,261,000 | -10.2% | 31,036 | -3.9% | 0.01% | -16.7% |
| Q3 2021 | $1,405,000 | +20.4% | 32,286 | +30.8% | 0.01% | +20.0% |
| Q2 2021 | $1,167,000 | -13.8% | 24,691 | -6.5% | 0.01% | 0.0% |
| Q1 2021 | $1,354,000 | -40.8% | 26,406 | -69.1% | 0.01% | +42.9% |
| Q4 2020 | $2,288,000 | – | 85,422 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bill & Melinda Gates Foundation | 1,559,142 | $39,700,000 | 30.52% |
| SB INVESTMENT ADVISERS (UK) LTD | 22,216,644 | $565,858,000 | 4.50% |
| Zebra Capital Management LLC | 25,419 | $647,000 | 1.90% |
| Alaska Permanent Fund Corp | 2,300,000 | $58,581,000 | 0.84% |
| CLARK ESTATES INC/NY | 180,000 | $4,585,000 | 0.79% |
| Temasek Holdings (Private) Ltd | 5,602,553 | $142,697,025 | 0.78% |
| SECTOR GAMMA AS | 110,223 | $2,807,000 | 0.63% |
| Avidity Partners Management LP | 758,211 | $19,312,000 | 0.44% |
| New Vernon Capital Holdings II LLC | 14,501 | $369,000 | 0.30% |
| DUALITY ADVISERS, LP | 116,415 | $2,965,000 | 0.29% |